• Bruce Peatey appointed as new CEO of PolyNovo, effective 1st December 2025
• Peatey has extensive experience in healthcare, medical devices and biotechnology companies, including leading the US, Canadian and Latin American markets at Dentsply Sirona
• Peatey's expertise in distribution strategies and relationships with major distributors will be instrumental as PolyNovo expands into new markets

PolyNovo Limited has announced the appointment of Mr. Bruce Peatey as the company's new Chief Executive Officer, effective 1st December 2025. Peatey is an experienced executive with a background in healthcare, medical devices and biotechnology companies. Most recently, he ran the US, Canadian and Latin American markets for Dentsply Sirona, where he generated over $1.3 billion USD in revenue in fiscal year 2024. Prior to that, Peatey was responsible for the Asia Pacific region at Dentsply Sirona, contributing significantly to the Rest of World's total revenue of over $900 million USD in 2024. Peatey has strong skills in managing quality and regulatory functions, which will be valuable as PolyNovo scales operations and moves into new regulatory markets. He has successfully launched new products across existing markets, particularly in the Asia-Pacific region. Peatey is known for his ability to align teams with corporate strategy, foster engagement of staff across geographies, and uphold governance standards. Prior to Dentsply Sirona, Peatey has worked in the smaller ASX listed company environment, as well as in various roles with multinational companies, including Abbott Laboratories, Baxter Healthcare and Biosensors International. His experience encompasses strategic business development, market expansion, new product launches, ERP system rollouts, implementation of new structures, fostering of high-performance teams, and navigation of tariffs and various Government and regulatory activities. PolyNovo's Chairman, David Williams, highlighted Peatey's expertise in navigating distribution strategies, including his established relationships with major dental distributors like Henry Schein, which will be instrumental as PolyNovo expands into the outpatient market and broadens its international presence.

Peatey expressed his excitement to lead PolyNovo's next phase of expansion into new markets, broader clinical applications, and deeper partnerships, while continuing to build on the company's strong foundation.